The Vigabatrin REMS Program is needed by the FDA to guarantee notified risk-benefit choices before starting treatment, and to ensure ideal use vigabatrin while individuals are treated. It is not possible for your healthcare provider to recognize when vision loss will take place.
It is suggested that your doctor examination your (or your child's) vision prior to or within 4 weeks after starting SABRIL and at least every 3 months throughout treatment up until SABRIL is stopped. Tell your healthcare provider if you or your child have any kind of adverse effects that bothers you or that does not disappear.
If seizures obtain worse, inform your health care company right away. You and your healthcare provider will need to choose if you should take SABRIL while you are expecting. One of the most typical adverse effects of SABRIL in adults include: blurred vision, sleepiness, lightheadedness, problems walking or feeling uncoordinated, drinking (trembling), and fatigue.